Weekly Analysts’ Ratings Updates for Nuvation Bio (NUVB)

Several analysts have recently updated their ratings and price targets for Nuvation Bio (NYSE: NUVB):

• 11/4/2025 – Nuvation Bio was given a new $8.00 price target on by analysts at JMP Securities.
• 11/4/2025 – Nuvation Bio had its “market outperform” rating reaffirmed by analysts at Citigroup Inc..
• 11/4/2025 – Nuvation Bio had its price target raised by analysts at Royal Bank Of Canada from $7.00 to $8.00. They now have an “outperform” rating on the stock.
• 11/4/2025 – Nuvation Bio had its price target raised by analysts at Citizens Jmp from $6.00 to $8.00. They now have a “market outperform” rating on the stock.
• 10/13/2025 – Nuvation Bio had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $6.00 price target on the stock.
• 10/8/2025 – Nuvation Bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/30/2025 – Nuvation Bio is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $10.00 price target on the stock.
• 9/30/2025 – Nuvation Bio is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $10.00 price target on the stock.
• 9/27/2025 – Nuvation Bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/19/2025 – Nuvation Bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.

Insider Buying and Selling at Nuvation Bio

In other news, insider Gary Hattersley sold 100,000 shares of the stock in a transaction on Monday, October 27th. The stock was sold at an average price of $5.02, for a total transaction of $502,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 29.93% of the company’s stock.

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.